Vaccination of domestic animals with a novel oral vaccine ...
Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with...
Transcript of Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with...
![Page 1: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/1.jpg)
Immunology of BVDV Vaccination
James A. Roth, DVM, PhD
Center for Food Security and Public HealthCollege of Veterinary Medicine
Iowa State University
![Page 2: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/2.jpg)
Issues Regarding BVDV Vaccine Efficacy
• Cross protection– Between types 1 and 2– Within types due to antigenic variation
• Fetal protection• Efficacy in distressed cattle• Maternal antibody interference• Onset and duration of immunity• Efficacy when administered with other
vaccines
![Page 3: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/3.jpg)
Issues Regarding BVDV Vaccine Safety
• Immunosuppression by MLV BVDV • Safety in distressed cattle• Safety in pregnant animals• Induction of mucosal disease• Injection site lesions
– Route of administration– Adjuvants
• Contamination with extraneous BVDV
![Page 4: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/4.jpg)
Pathogenic Mechanisms
Defense Mechanisms
Adherence to mucosa Mucosal antibody (IgA)Parasites IgEExotoxin/Endotoxin Neutralizing antibodyViremia Neutralizing antibodySepticemia Opsonizing antibodyIntracytoplasmic growthVirus replication
Cytotoxic T cells Types 1 and 2 Interferons
Growth in phagosome Th1 cytokinesInfect epithelial cells Gamma delta T cells
![Page 5: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/5.jpg)
Pathogenic Mechanisms
Defense Mechanisms
Adherence to mucosa Mucosal antibody (IgA)Parasites IgEExotoxin/Endotoxin Neutralizing antibodyViremia Neutralizing antibodySepticemia Opsonizing antibodyIntracytoplasmic growthVirus replication
Cytotoxic T cells Types 1 and 2 Interferons
Growth in phagosome Th1 cytokinesInfect epithelial cells Gamma delta T cells
![Page 6: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/6.jpg)
Internal and external antigens surrounding the viral genetic material
external antigens internal antigens
non-protective protective non-protective
Roitt, I., Brostoff, J., Male, D. Immunology. 1985
![Page 7: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/7.jpg)
Detection of Antigen Specific T Cell-Mediated Immunity to Bovine Respiratory
Disease Viruses by Flow Cytometry
![Page 8: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/8.jpg)
Cell-Mediated Immunity (CMI)
Functional T-cell subsets
CD4
αβ T
Th1 Th2
CD8
γδT
![Page 9: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/9.jpg)
T Cell Activation
Unstimulated Stimulated
Antigen stimulated
T T
CD25 (IL-2R)
Cell surface marker
Cytokine
![Page 10: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/10.jpg)
Five-color Flow Cytometry
1
2
5
4
T
T
T
3
• Simultaneous labeling of 3 T cell subset markers (CD4, CD8, γδ TCR), activation marker CD25 and intracellular IFNγ.
• Detects co-expression of double positive cells, e.g. CD8 and γδ TCR.
• Identifies all T cell subsets that express CD25 and/or IFNγ in the same well.
![Page 11: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/11.jpg)
CD25 Data Tabulation
•Percentage of the T cell population that is CD25+ from both unstimulated and antigen-stimulated cells
•Mean fluorescence intensity (MFI) of CD25 expression
•CD25 Expression Index calculation
(%CD25+ of stimulated cells)(MFI) (%CD25+ of unstimulated cells)(MFI)
CD25 Expression Index =
![Page 12: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/12.jpg)
Monitoring T Cell Responses by CD25 and IFNγ Expression Analysis
• Immunize calves
• Collect blood samples from vaccinated and control calves
![Page 13: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/13.jpg)
Monitoring T Cell Responses by CD25 and IFNγ Expression Analysis
• Isolate peripheral blood mononuclear cells (PBMC)
• Incubate PBMC in vitrowith antigens in microtiter plates
• Stain cell surface markers and activation markers
![Page 14: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/14.jpg)
Influence of Maternal Antibody on Development of Memory T cells after
Exposure to BVDV
Janice Endsley1, Julia Ridpath2, John Neill2, James Roth1
1Iowa State University, 2USDA ARS National Animal Disease Center
![Page 15: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/15.jpg)
Hypothesis
Calves infected with Bovine Viral Diarrhea virus in the presence of passive antibody will develop CD4, CD8, and γδ T cells specific for BVDV, without a detectable antibody response and will be protected from subsequent challenge.
![Page 16: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/16.jpg)
Experimental Design
• Pooled colostrum from BVDV hyper-immunized cows was fed to 12 calves.
• Six of 12 calves were inoculated with BVDV type 2 (strain 1373) at 6 to 20 days of age.
• Three calves received no colostrum and no BVDV inoculation.
• Three calves received no colostrum and were challenged at 6 to 20 days of age (all died).
• All surviving calves were challenged with BVDV type 2 (strain 1373) at 8 to 9 months of age.
![Page 17: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/17.jpg)
Temperature (After 1st Inoculation)
100
101
102
103
104
105
106
107
0 2 4 6 8 10 12 14 16 18 20Day Post Inoculation
No ColostrumFirst inoculation Colostrum
Tem
p (F
)
![Page 18: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/18.jpg)
Neutralizing Antibody Responses to BVDV Type 2
0
0.5
1
1.5
2
2.5
3
3.5
4
1 2 3 4 5 6 7 8 9 10
Month after first BVDV inoculation
SV
N T
iter (
log1
0)
Colostrum Colostrum, BVDV
![Page 19: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/19.jpg)
Activation of CD4 T Cells by BVDV Type 2
0
5
10
15
20
25
30
0-10 wks 11-20 wks 21-32 wks
Colostrum Colostrum, BVDVWeeks after first BVDV inoculation
Exp
ress
ion
Inde
x
P = 0.07
P = 0.04
![Page 20: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/20.jpg)
Activation of CD8 T Cells by BVDV Type 2
0
5
10
15
20
25
30
0-10 wks 11-20 wks 21-32 wks
P = 0.008
P = 0.10
Colostrum Colostrum, BVDVWeeks after first BVDV inoculation
Exp
ress
ion
Inde
x
![Page 21: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/21.jpg)
Activation of γδ T Cells by BVDV Type 2
0
5
10
15
20
25
30
0-10 wks 11-20 wks 21-32 wks
P = 0.04 P = 0.006P = 0.04
Colostrum Colostrum, BVDVWeeks after first BVDV inoculation
Exp
ress
ion
Inde
x
![Page 22: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/22.jpg)
IFNγ Production (ELISA)
0
20
40
60
80
100
120
140
0 - 10 Weeks 11 - 20 Weeks 21 - 32 Weeks
Colostrum, No BVDV Colostrum, BVDV
IFN
γng
/ml
![Page 23: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/23.jpg)
Temperature (After Challenge)
100
101
102
103
104
105
106
107
0 2 4 6 8 10 12 14 16 18 20Days post challenge
Challenge
Colostrum + VirusColostrum + Virus
ColostrumColostrum
No ColostrumNo Colostrum
Tem
p (F
)
![Page 24: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/24.jpg)
Virus Isolation from Buffy Coats (After Challenge)
Days post challenge
Group 2 4 6 8 10 12
Colostrum + BVDV 0/5 0/5 0/5 0/5 0/5 0/5
Colostrum 3/6 4/6 6/6 6/6 2/6 2/6
No colostrum 2/3 3/3 3/3 3/3 0/3 0/3
![Page 25: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/25.jpg)
Mean SN Titers to BVDV 1373 After Challenge
Colostrum + VirusColostrumNo Colostrum
![Page 26: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/26.jpg)
Induction of Antigen Specific T Cell Subset Activation to Bovine Respiratory Disease
Viruses by MLV Vaccine
Platt, R., W. Burdett, and J. A. Roth. 2006. Induction of antigen specific T cell subset activation to bovine respiratory disease viruses by a modified-live virus vaccine. Am J Vet Res, In press.
![Page 27: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/27.jpg)
Experimental Design
• Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine – Intervet)
– Week 0
• Blood collection for CMI assay
– Weeks 0, 4, 5, 6, 8, 24, 25, 26, 27
• Challenge
– BHV-1 Cooper strain on week 25 (2 ml of 108 TCID50/ml)
• Nasal secretion collection for virus titration
– Days 0-14 post-challenge
![Page 28: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/28.jpg)
CMI assay
In vitro stimulation of PBMC• Unstimulated
• Mitogen stimulated
• Live virus stimulated
– BHV-1 (Bovishield®)
– BRSV (Bovishield®)
– BVDV type 1 (TGAN-NADC)
– BVDV type 2 (890-NADC)
![Page 29: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/29.jpg)
BHV-1 ResultsCD25 Expression Index
0
10
20
30
40
50
60
70
80
90
Mea
n(W
eek
0)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
70
80
90
Mea
n(W
eek
4568
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
70
80
90
Mea
n(W
eek
2425
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
70
80
90
Mea
n(W
eek
26)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
70
80
90
Mea
n(W
eek
27)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
Pre-vaccination
Week 0
Post-vaccination
Weeks 4, 5, 6, 8
Subset All PBMC CD4 CD8
gd Non T cells Statistically significant (p<0.01) (p<0.05)
Pre-challenge
Weeks 24, 25
Week 1 post-challenge
Week 26
Week 2 post-challenge
Week 27
![Page 30: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/30.jpg)
BRSV ResultsCD25 Expression Index
Pre-vaccination
Week 0
Post-vaccination
Weeks 4, 5, 6, 8
0
10
20
30
40
Mea
n(W
eek
0)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
Mea
n(W
eek
4568
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
Mea
n(W
eek
2425
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
Mea
n(W
eek
26)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
Mea
n(W
eek
27)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
Subset All PBMC CD4 CD8
gd Non T cells Statistically significant (p<0.01) (p<0.05)
Pre-challenge
Weeks 24, 25
Week 1 post-challenge
Week 26
Week 2 post-challenge
Week 27
![Page 31: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/31.jpg)
BVDV Type 1 ResultsCD25 Expression Index
Pre-vaccination
Week 0
Post-vaccination
Weeks 4, 5, 6, 8
0
10
20
30
40
50
60
Mea
n(W
eek
0)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
Mea
n(W
eek
4568
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
Mea
n(W
eek
2425
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
Mea
n(W
eek
26)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
Mea
n(W
eek
27)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
Subset All PBMC CD4 CD8
gd Non T cells Statistically significant (p<0.01) (p<0.05)
Pre-challenge
Weeks 24, 25
Week 1 post-challenge
Week 26
Week 2 post-challenge
Week 27
![Page 32: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/32.jpg)
BVDV Type 2 ResultsCD25 Expression Index
Pre-vaccination
Week 0
Post-vaccination
Weeks 4, 5, 6, 8
0
10
20
30
40
50
60
Mea
n(W
eek
0)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
Mea
n(W
eek
4568
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
Mea
n(W
eek
2425
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
Mea
n(W
eek
26)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
0
10
20
30
40
50
60
Mea
n(W
eek
27)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
Subset All PBMC CD4 CD8
gd Non T cells Statistically significant (p<0.01) (p<0.05)
Pre-challenge
Weeks 24, 25
Week 1 post-challenge
Week 26
Week 2 post-challenge
Week 27
![Page 33: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/33.jpg)
BHV-1 Results∆ %IFNγ +
Pre-vaccination
Week 0
Post-vaccination
Weeks 4, 5, 6, 8
-2
-1
0
1
2
3
4
Mea
n(W
eek
0)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
4568
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
2425
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
26)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
27)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
Subset All PBMC CD4 CD8
gd Non T cells Statistically significant (p<0.01) (p<0.05)
Pre-challenge
Weeks 24, 25
Week 1 post-challenge
Week 26
Week 2 post-challenge
Week 27
![Page 34: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/34.jpg)
BRSV Results∆ %IFNγ +
Pre-vaccination
Week 0
Post-vaccination
Weeks 4, 5, 6, 8
-2
-1
0
1
2
3
4
Mea
n(W
eek
0)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
4568
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
2425
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
26)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
27)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
Subset All PBMC CD4 CD8
gd Non T cells Statistically significant (p<0.01) (p<0.05)
Pre-challenge
Weeks 24, 25
Week 1 post-challenge
Week 26
Week 2 post-challenge
Week 27
![Page 35: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/35.jpg)
BVDV Type 1 Results∆ %IFNγ +
Pre-vaccination
Week 0
Post-vaccination
Weeks 4, 5, 6, 8
-2
-1
0
1
2
3
4
Mea
n(W
eek
0)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
4568
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
2425
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
26)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
27)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
Subset All PBMC CD4 CD8
gd Non T cells Statistically significant (p<0.01) (p<0.05)
Pre-challenge
Weeks 24, 25
Week 1 post-challenge
Week 26
Week 2 post-challenge
Week 27
![Page 36: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/36.jpg)
BVDV Type 2 Results∆ %IFNγ +
Pre-vaccination
Week 0
Post-vaccination
Weeks 4, 5, 6, 8
Pre-challenge
Weeks 24, 25
Week 1 post-challenge
Week 26
Week 2 post-challenge
Week 27
-2
-1
0
1
2
3
4
Mea
n(W
eek
0)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
4568
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
2425
)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
26)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
-2
-1
0
1
2
3
4
Mea
n(W
eek
27)
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
All
PBM
C
CD
4
CD
8 gd
Non
T c
ells
Control Vaccinated
Subset within Group
Subset All PBMC CD4 CD8
gd Non T cells Statistically significant (p<0.01) (p<0.05)
![Page 37: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/37.jpg)
Virus Titration Results
Statistically significant (p<0.01) (p<0.05)
01234567
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Day post challenge
Log
viru
s tit
er
Mean control group Mean vaccinated group
![Page 38: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/38.jpg)
Post-challenge Body Temperature
Statistically significant (p<0.01) (p<0.05)
101.0
101.5
102.0
102.5
103.0
103.5
104.0
104.5
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Control Vaccinated
![Page 39: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/39.jpg)
Efficacy of Killed BVDV Vaccines for Induction of T Cell Mediated Immunity?
![Page 40: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/40.jpg)
Immunosuppression by BVDV and MLV BVDV Vaccine
![Page 41: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/41.jpg)
Suppression of Neutrophil Iodination by Virulent BVDV
ControlsNADL BVDV IN1015-74 BVDV IM
Roth et al, AJVR 42:244-250, 1981
![Page 42: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/42.jpg)
Suppression of Neutrophil Iodination by MLV BVDV and ACTH
Roth and Kaeberle, AJVR 44:2366-2372, 1983
![Page 43: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/43.jpg)
Goals for BVDV Vaccine
• Induce high and prolonged SN antibody titers• Induce strong CD4, CD8, and γδ T cell
responses• Induce active immunity in the presence of
passive antibody• Safe in pregnant cows• Not suppress native or acquired immune
defense mechanisms• Serve as a marker vaccine to aid BVD
eradication programs
![Page 44: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/44.jpg)
Approaches to Improved BVDV Vaccines
• New adjuvants to enhance T cell responses• Live vectored vaccines coding for protective
BVDV antigens• Identify and delete virulence and
immunosuppressive genes from BVDV for new generation MLV vaccines
• All three of these approaches:– Should induce CMI– Should not be immunosuppressive– Could serve as marker vaccines
![Page 45: Immunology of BVDV Vaccination...Am J Vet Res, In press. Experimental Design • Vaccination with modified-live virus vaccine (BHV-1, BRSV, BVDV types 1 and 2, and PI3) (Vista vaccine](https://reader034.fdocuments.us/reader034/viewer/2022051911/60013c470942eb333611943f/html5/thumbnails/45.jpg)